ClinicalTrials.gg
Not yet recruitingNCT07045012Updated Jul 1, 2025

The Relationship Between Osteoporosis and Sarcopenia Parameters in Postmenopausal Women Under 60

An observational study in Osteoporosis, sponsored by Beylikduzu State Hospital. Not yet recruiting. Open to female participants aged 50 Years to 59 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Beylikduzu State Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
52
Ages
50 Years to 59 Years
Sex
Female
01

Study summary

This cross-sectional study will include postmenopausal women under the age of 60 who visited the Physical Medicine and Rehabilitation outpatient clinic at Beylikdüzü State Hospital between June 25 and July 25, 2025. Participants must have undergone a bone mineral density (BMD) assessment within the past six months using Dual X-ray Absorptiometry (DXA). Both osteoporotic and non-osteoporotic patients will be enrolled. Sociodemographic data such as age, height, weight, and BMI will be recorded. Femoral neck and L1-L4 T-scores and BMD values will be obtained from existing DXA results. Information on osteoporosis treatment, presence of fecal incontinence, constipation, and medication use will be collected. In the second phase, sarcopenia will be assessed according to EWGSOP2 criteria using bioelectrical impedance analysis for skeletal muscle mass, handgrip strength, and the five-time sit-to-stand test. Differences between the osteoporotic and non-osteoporotic groups will be analyzed.

02

Conditions studied

  • Osteoporosis

Browse trials for

03

In context

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

This study's planned enrollment of 52 is below the median of 160 across 456 observational studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Beylikduzu State Hospital is the lead sponsor of 23 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 59 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

Postmenopausal women under 60 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women under 60 years of age who are .
  • Patients with or without a diagnosis of osteoporosis:

Osteoporosis group: T-score ≤ -2.5 in femoral neck or L1-L4 region. Control group: T-score ≥ -1.0 in femoral neck and L1-L4 region.

-Patients who provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study.
  • Presence of neuromuscular diseases that could cause muscle loss.
  • History of infection, recent surgery, or trauma.
  • Presence of psychiatric disorders.
  • Cognitive impairment that could interfere with test performance or data reliability.
  • Use of medications that could affect study outcomes (e.g., , muscle relaxants, or medications influencing bone/muscle metabolism).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
52 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Skeletal Muscle Mass

    Measured by bioelectrical impedance analysis (BIA), this assesses the amount of muscle tissue in the body. Low skeletal muscle mass indicates sarcopenia.

    Time frame: 0 day

  2. Handgrip Strength

    This is a simple test to measure muscle strength. Reduced handgrip strength is a sign of sarcopenia.

    Time frame: 0 day

  3. 5 times chair stand test

    The Five Times Sit-to-Stand Test is a simple and widely used functional assessment tool to evaluate lower extremity muscle strength, balance, and mobility.

    Time frame: 0 day

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Jul 2025, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2025
First posted
Jul 1, 2025
StartEst.
Jun 25, 2025
Primary completionEst.
Jul 25, 2025
CompletionEst.
Jul 25, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07045012
Lead sponsor
Beylikduzu State Hospital
Responsible party
Busra Sirin (Principle Investigator, Beylikduzu State Hospital) — Principal investigator
First posted
Jul 1, 2025
Start date
Jun 25, 2025 (estimated)
Primary completion
Jul 25, 2025 (estimated)
Completion
Jul 25, 2025 (estimated)
Last update
Jul 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion